Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.

The E/E′ ratio, an indicator of the function of left ventricle filling, was slightly increased in the obese ZSF1 group compared to that of the lean control group, however, this effect did not reach statistical significance (Fig. 2 ).

also in 111,027 other papers